rs2535261
Variant names:
Your query was ambiguous. Multiple possible variants found:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_206809.4(MOG):c.436+859G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.17 ( 2048 hom., cov: 20)
Consequence
MOG
NM_206809.4 intron
NM_206809.4 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -2.29
Publications
1 publications found
Genes affected
MOG (HGNC:7197): (myelin oligodendrocyte glycoprotein) The product of this gene is a membrane protein expressed on the oligodendrocyte cell surface and the outermost surface of myelin sheaths. Due to this localization, it is a primary target antigen involved in immune-mediated demyelination. This protein may be involved in completion and maintenance of the myelin sheath and in cell-cell communication. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]
MOG Gene-Disease associations (from GenCC):
- narcolepsy 7Inheritance: Unknown Classification: LIMITED Submitted by: Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-1.01).
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.269 is higher than 0.05.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| MOG | NM_206809.4 | c.436+859G>A | intron_variant | Intron 2 of 7 | ENST00000376917.8 | NP_996532.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| MOG | ENST00000376917.8 | c.436+859G>A | intron_variant | Intron 2 of 7 | 1 | NM_206809.4 | ENSP00000366115.3 |
Frequencies
GnomAD3 genomes AF: 0.168 AC: 20635AN: 123150Hom.: 2046 Cov.: 20 show subpopulations
GnomAD3 genomes
AF:
AC:
20635
AN:
123150
Hom.:
Cov.:
20
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.168 AC: 20652AN: 123224Hom.: 2048 Cov.: 20 AF XY: 0.171 AC XY: 9858AN XY: 57514 show subpopulations
GnomAD4 genome
AF:
AC:
20652
AN:
123224
Hom.:
Cov.:
20
AF XY:
AC XY:
9858
AN XY:
57514
show subpopulations
African (AFR)
AF:
AC:
8832
AN:
32224
American (AMR)
AF:
AC:
1221
AN:
10634
Ashkenazi Jewish (ASJ)
AF:
AC:
354
AN:
3190
East Asian (EAS)
AF:
AC:
861
AN:
4202
South Asian (SAS)
AF:
AC:
551
AN:
3274
European-Finnish (FIN)
AF:
AC:
669
AN:
5904
Middle Eastern (MID)
AF:
AC:
52
AN:
222
European-Non Finnish (NFE)
AF:
AC:
7764
AN:
61232
Other (OTH)
AF:
AC:
261
AN:
1534
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.485
Heterozygous variant carriers
0
706
1411
2117
2822
3528
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
218
436
654
872
1090
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.